Avalyn Pharma Inc.
Clinical trials sponsored by Avalyn Pharma Inc., explained in plain language.
-
New inhaled therapy aims to slow lung scarring in IPF
Disease control Recruiting nowThis study tests an inhaled version of the drug nintedanib (called AP02) in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 160 adults aged 40 and older who are not currently on IPF treatment will take either a low o…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New inhaled drug for lung scarring moves to Long-Term safety check
Disease control Recruiting nowThis study looks at the long-term safety of an inhaled drug (AP01) for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. About 340 participants will receive the drug and be monitored for side effects …
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC